Drug–drug interaction potential and clinical pharmacokinetics of enerisant, a novel potent and selective histamine H₃ receptor antagonist

References

• Arrang, J.M., Garbarg, M., and Schwartz, J.C., 1983. Auto-inhibition of brain histamine release mediated by a novel class (H3) of histamine receptor. Nature, 302, 832–837.
   PubMed Web of Science ®Google Scholar
• Barateau, L., Lopez, R., and Dauvilliers, Y., 2016. Treatment options for narcolepsy. CNS drugs, 30 (5), 369–379.
   PubMed Web of Science ®Google Scholar
• Bioprojet Pharma, 2016. Wakix (pitolisant): summary of product characteristics. Available from: https://www.ema.europa.eu/en/documents/product-information/wakix-epar-product-information_en.pdf [last accessed 23 Oct 2020]
   Google Scholar
• Bonaventure, P., et al., 2007. Histamine H3 receptor antagonists: from target identification to drug leads. Biochemical pharmacology, 73 (8), 1084–1096.
   PubMed Web of Science ®Google Scholar
• Brunton, L.L., Chabner, B.A,, and Knollmann, B.C., 2011. Goodman and Gilman's the pharmacological basis of therapeutics. 12th edition. New York, NY: McGraw-Hill Education.
   Google Scholar
• Burt, H.J., et al., 2016. Metformin and cimetidine: physiologically based pharmacokinetic modelling to investigate transporter mediated drug–drug interactions. European journal of pharmaceutical sciences : official journal of the European federation for pharmaceutical sciences, 88, 70–82.
   PubMed Web of Science ®Google Scholar
• Cho, S.K. and Chung, J.Y., 2016. The MATE1 rs2289669 polymorphism affects the renal clearance of metformin following ranitidine treatment. International journal of clinical pharmacology and therapeutics, 54 (4), 253–262.
   PubMed Web of Science ®Google Scholar
• Chu, X.Y., et al., 2007. Transport of the dipeptidyl peptidase-4 inhibitor sitagliptin by human organic anion transporter 3, organic anion transporting polypeptide 4C1, and multidrug resistance P-glycoprotein. The journal of pharmacology and experimental therapeutics, 321 (2), 673–683.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency., 2012. Guideline on the investigation of drug interactions. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-investigation-drug-interactions-revision-1_en.pdf. [last accessed 23 Oct 2020]
   Google Scholar
• Giacomini, K.M., International Transporter Consortium. et al. (2010). Membrane transporters in drug development. Nature reviews. Drug discovery, 9 (3), 215–236.
   PubMed Web of Science ®Google Scholar
• Hino, N., et al., 2020. A novel potent and selective histamine H3 receptor antagonist enerisant: in vitro profiles, in vivo receptor occupancy, and wake-promoting and procognitive effects in rodents. The journal of pharmacology and experimental therapeutics, 375 (2), 276–285.
   PubMed Web of Science ®Google Scholar
• Huang, Z.L., et al., 2006. Altered sleep-wake characteristics and lack of arousal response to H3 receptor antagonist in histamine H1 receptor knockout mice. Proceedings of the national academy of sciences of the United States of America, 103 (12), 4687–4692.
   PubMed Web of Science ®Google Scholar
• Hutzler, J.M., Cook, J., and Fleishaker, J.C., 2011. Drug–drug interactions: designing development programs and appropriate product labeling. In: Bonate, P.L., Howard, D.R., eds. Pharmacokinetics in drug development. New York: Springer, 21–56.
   Google Scholar
• Karyekar, C.S., et al., 2004. Renal interaction between itraconazole and cimetidine. The journal of clinical pharmacology, 44 (8), 919–927.
   PubMed Web of Science ®Google Scholar
• Lai, Y., Sampson, K.E., and Stevens, J.C., 2010. Evaluation of drug transporter interactions in drug discovery and development. Combinatorial chemistry & high throughput screening, 13 (2), 112–134.
   PubMed Web of Science ®Google Scholar
• Lamb, Y.N., 2020. Pitolisant: a review in narcolepsy with or without cataplexy. CNS Drugs, 34 (2), 207–218.
   PubMed Web of Science ®Google Scholar
• Le, S., et al., 2008. Correlation between ex vivo receptor occupancy and wake-promoting activity of selective H3 receptor antagonists. The journal of pharmacology and experimental therapeutics, 325 (3), 902–909.
   PubMed Web of Science ®Google Scholar
• Leurs, R., et al., 2011. En route to new blockbuster anti-histamines: surveying the offspring of the expanding histamine receptor family. Trends in pharmacological sciences, 32 (4), 250–257.
   PubMed Web of Science ®Google Scholar
• Lin, J.S., 2000. Brain structures and mechanisms involved in the control of cortical activation and wakefulness, with emphasis on the posterior hypothalamus and histaminergic neurons. Sleep medicine reviews, 4 (5), 471–503.
   PubMed Web of Science ®Google Scholar
• Lin, J.S., et al., 1996. Histaminergic descending inputs to the mesopontine tegmentum and their role in the control of cortical activation and wakefulness in the cat. The journal of neuroscience : the official journal of the society for neuroscience, 16 (4), 1523–1537.
   PubMed Web of Science ®Google Scholar
• Madan, A., et al., 2003. Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes. Drug metabolism and disposition: the biological fate of chemicals, 31 (4), 421–431.
   PubMed Web of Science ®Google Scholar
• Ohayon, M.M., 2013. Narcolepsy is complicated by high medical and psychiatric comorbidities: a comparison with the general population. Sleep medicine, 14 (6), 488–492.
   PubMed Web of Science ®Google Scholar
• Paris, B.L., et al., 2009. In vitro inhibition and induction of human liver cytochrome p450 enzymes by milnacipran. Drug metabolism and disposition, 37, 2045–2054.
   PubMed Web of Science ®Google Scholar
• Parmentier, R., et al., 2002. Anatomical, physiological, and pharmacological characteristics of histidine decarboxylase knock-out mice: evidence for the role of brain histamine in behavioral and sleep-wake control. The journal of neuroscience : the official journal of the society for neuroscience, 22 (17), 7695–7711.
   PubMed Web of Science ®Google Scholar
• Parmentier, R., et al., 2007. The brain H3-receptor as a novel therapeutic target for vigilance and sleep-wake disorders. Biochemical pharmacology, 73 (8), 1157–1171.
   PubMed Web of Science ®Google Scholar
• Parmentier, R., et al., 2016. Role of histamine H1-receptor on behavioral states and wake maintenance during deficiency of a brain activating system: a study using a knockout mouse model. Neuropharmacology, 106, 20–34.
   PubMed Web of Science ®Google Scholar
• PMDA, 2018. Guideline on drug interaction for drug development and appropriate provision of information. Available from: https://www.pmda.go.jp/files/000225191.pdf [Japanese] [last accessed 23 Oct 2020].
   Google Scholar
• Robertson, P., et al., 2000. In vitro inhibition and induction of human hepatic cytochrome P450 enzymes by modafinil. Drug metabolism and disposition: the biological fate of chemicals, 28 (6), 664–671.
   PubMed Web of Science ®Google Scholar
• Rowland, A., et al., 2018. Evaluation of modafinil as a perpetrator of metabolic drug-drug interactions using a model informed cocktail reaction phenotyping trial protocol. British journal of clinical pharmacology, 84 (3), 501–509.
   PubMed Web of Science ®Google Scholar
• Russel, F.G.M., 2010. Enzyme- and transporter-based drug–drug interactions: progress and future challenges. In: Pang, K.S., Rodrigues, A.D., Peter, R.M., eds. Transporters: importance in drug absorption, distribution, and removal. New York: Springer, 27–49.
   Google Scholar
• Scheen, A.J., 2014. Drug-drug interactions with sodium-glucose cotransporters type 2 (SGLT2) inhibitors, new oral glucose-lowering agents for the management of type 2 diabetes mellitus. Clinical pharmacokinetics, 53 (4), 295–304.
   PubMed Web of Science ®Google Scholar
• Tsuda, M., et al., 2009. Involvement of human multidrug and toxin extrusion 1 in the drug interaction between cimetidine and metformin in renal epithelial cells. The journal of pharmacology and experimental therapeutics, 329 (1), 185–191.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration, 2020. Guidance for industry. In vitro drug interaction studies – cytochrome P450 enzyme- and transporter-mediated drug interactions. Available from: https://www.fda.gov/media/134582/download [last accessed 23 Oct 2020].
   Google Scholar